Evidence map›Paper›PMID 33833366›Full record

ArticleScientific reports2021

Dimeric mimetic of BDNF loop 4 promotes survival of serum-deprived cell through TrkB-dependent apoptosis suppression.

L F Zainullina, Yu V Vakhitova, A Yu Lusta, T A Gudasheva, S B Seredenin

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Peptides Derived from Growth Factors to Treat Alzheimer's Disease.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

L F Zainullina *Federal State Budgetary Institution "Research Zakusov Institute of Pharmacology", 125315, Baltiyskaya str. 8, Moscow, Russia.
Yu V Vakhitova *Federal State Budgetary Institution "Research Zakusov Institute of Pharmacology", 125315, Baltiyskaya str. 8, Moscow, Russia. vakhitova@academpharm.ru.
A Yu LustaFederal State Budgetary Institution "Research Zakusov Institute of Pharmacology", 125315, Baltiyskaya str. 8, Moscow, Russia.
T A GudashevaFederal State Budgetary Institution "Research Zakusov Institute of Pharmacology", 125315, Baltiyskaya str. 8, Moscow, Russia.
S B SeredeninFederal State Budgetary Institution "Research Zakusov Institute of Pharmacology", 125315, Baltiyskaya str. 8, Moscow, Russia.
Institute of Pharmacology Russian Academy of Medical Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain-derived neurotrophic factor (BDNF) is involved in the regulation of neuronal cell growth, differentiation, neuroprotection and synaptic plasticity. Although aberrant BDNF/TrkB signaling is implicated in several neurological, neurodegenerative and psychiatric disorders, neurotrophin-based therapy is challenging and is limited by improper pharmacokinetic properties of BDNF. Dimeric dipeptide compound GSB-106 (bis-(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide) has earlier been designed to mimic the TrkB-interaction 4 loop of BDNF. It displayed protective effect in various cell-damaging models in vitro. Animal studies uncovered antidepressive and neuroprotective properties upon GSB-106 per os administration. Current study shows that GSB-106 acts similarly to BDNF, promoting survival of serum-deprived neuronal-like SH-SY5Y cells. 100 nmol concentration of GSB-106 provided maximum neurotrophic effect, which corresponds to about 37% of the maximum effect provided by BDNF. Protective properties of GSB-106 arise from its ability to counteract cell apoptosis via activation of TrkB-dependent pro-survival mechanisms, including inactivation of pro-apoptotic BAD protein and suppression of caspases 9 and 3/7. Thus, our study has characterized neurotrophic activity of small dimeric compound GSB-106, which mimics certain biological functions of BDNF and neurotrophin-specific protective mechanisms. GSB-106 also displays similarities to some known low weight peptide and non-peptide TrkB ligands.

Indexed as

ApoptosisCell Line, TumorDipeptidesHumansMembrane GlycoproteinsMolecular MimicryNeuroprotective AgentsReceptor, trkBbis-(N-monosuccinyl-l-seryl-l-lysine)hexamethylenediamideDipeptidesMembrane GlycoproteinsNeuroprotective AgentsReceptor, trkBtropomyosin-related kinase-B, human

Identifiers

PMID33833366
PMCPMC8032782
OpenAlexW3141105559

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.